Endo Plans to Open New Manufacturing Facility in India
Introduction:
Endo, Inc. announces its plans to open a new aseptic manufacturing facility in Indore, India.
Features:
This cutting-edge 20,000-square-foot facility is specifically designed for the aseptic manufacturing of sterile injectable products, including medicines in vials and, eventually, syringes.
Endo has also received the U.S. Food and Drug Administration (FDA) approval for commercial production of VASOSTRICT® (vasopressin injection, USP) at its new Indore facility. This marks the Indore facility's first U.S. FDA approval, highlighting Endo’s commitment to adhering to rigorous quality standards and expanding its global manufacturing footprint.
The Indore facility is designed specifically for aseptic manufacturing of sterile injectable products—a difficult and highly specialised production capability. The site is expected to eventually produce medicines in syringes, in addition to vials.
Endo plans to apply for additional product approvals for the Indore site, further supporting the long-term growth of its Injectable Solutions business.
Production at the Indore facility is expected to begin in 2026.
Specifications:
Nam e : Endo
Type: New Construction
Year: 2026
